Video

How do we get the next 10 years right? w/ Joanna Shields, CogX

For the opening keynote of CogX 2020, our CEO Joanna Shields shared inspiration for the next decade, and answered the question “how do we get the next 10 years right”?

We had entered 2020 with such high hopes and dreams for the innovations that awaited us in the coming decade. Yet we were barely out of the gates when our world of infinite possibilities was brought to its knees by a deadly virus. The challenges that followed have been unprecedented in our lifetimes. 

As the disease raged through our communities and lockdowns were enforced, we all watched the daily news recount the number of souls who had lost their lives to COVID-19.  The profound economic shock continues to reverberate, and expose deep inequities in our society and in how we care for our citizens.

Our journey into this strange new normal also made us painfully aware of our own vulnerabilities and the fragility of human life. Above all, we have been reminded that our most valuable currency is not measured in wealth or possessions, but rather through our health.  

So, why can’t we build a world where no disease goes untreated? Why, with all of the advances in technology, are so many people still suffering from disease? The economic and development models urgently need to change. Patients deserve better. We must leverage breakthrough technologies for the benefit of all.

Above all, getting the next 10 years right demands leaders with empathy who care about their fellow citizens and are prepared to work to end injustice and create opportunities for all.

Watch the full speech here:


More Posts

You Might Also Like

Blog
Transforming drug discovery with AI: how we’re building and nurturing the best talent for the job
At BenevolentAI, we are on a mission to bring life-changing medicines to patients, and we are looking for collaborative, mission-driven people to join our tech, drug discovery and business operations teams in London, Cambridge and New York.
Oct 17, 2021
News
BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies
BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.
Oct 14, 2021
Blog
Measuring bias: moving towards more inclusive health research outcomes #stateofai
Having shared our open-source Diversity Analysis Tool last year, we were tasked to investigate and demonstrate the lack of diversity in biomedical data as part of the State of AI Report 2021.
Oct 12, 2021
Blog
Expert-augmented computational drug discovery for rare diseases
Combining scientific expertise, computational tools and our AI-enhanced biomedical knowledge graph to successfully uncover a new drug combination for treating a rare brain cancer in children.
Sep 28, 2021
News
BenevolentAI appoints Dr John Orloff to its Board of Directors
Biopharmaceutical veteran Dr John Orloff joins the BenevolentAI Board as a Non-Executive Director as it scales the development of its leading AI-derived drug pipeline.
Sep 9, 2021
Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021